LEIDEN, The Netherlands, August 30, 2007-Biotech company
Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM)
announced today positive safety and efficacy results from its
European randomized placebo-controlled Phase III clinical trial of
Rhucin® for the acute treatment of Hereditary Angieoedema
(HAE). The positive results from an interim analysis of its
European randomized placebo-controlled Phase III clinical trial
follow earlier studies showing the strong positive effect of
Rhucin® coupled to an excellent safety profile.

The Phase III double-blind placebo-controlled study with
Rhucin® was conducted at several centres across Europe. The
trial assessed the safety and efficacy of Rhucin® in patients
who presented with different sites of acute HAE attacks. In the
analysis, data were analyzed from the first 28 patients randomized
to either Rhucin® or placebo. Patients receiving Rhucin®
reported first relief at a median time of 60 minutes compared to
8.5 hours for those patients who received placebo. The primary
endpoint, time to beginning of symptom relief, achieved statistical
significance with a p-value of 0.0009 using the so-called log-rank
test which is a common type of statistical analysis in these
studies. Typically, if the p-value is below 0.05, the data are
considered to be statistically significant. The result achieved at
the primary endpoint was also clinically relevant.

In addition, patients receiving Rhucin® reported minimal
symptoms at a median time of 6.1 hours compared with 20.2 hours for
patients who received placebo. The secondary endpoint which
measured time to minimal symptoms, achieved statistical
significance with a p-value of 0.0038. The result achieved at the
secondary endpoint was also clinically relevant. The analysis
demonstrated that 100% of patients in the Rhucin® group
responded to treatment and that all of these patients experienced
sustained relief without a relapse of their attack symptoms.

The safety experience from the trial indicates that Rhucin®
continues to be very well tolerated and there were no drug-related
adverse events reported during this study. The Independent Data
Monitoring Committee reviewed these results and recommended that
the Company discontinue further randomized treatments for
methodological and ethical reasons. Randomized treatments in the
trial have now been stopped and the study will be amended so
patients may continue to have access to Rhucin® through
open-label treatments.

The positive results from the study have been provided to the
Committee for Medicinal Products (CHMP) of the EMEA in support of
the Marketing Authorization for Rhucin® in Europe. Data from
the analysis were also submitted to the FDA in the US, where an
independent placebo-controlled randomized clinical trial assessing
the safety and efficacy of Rhucin® is expected to be completed
in the next few months.

Dr. Bruno Giannetti, Chief Operations Officer of Pharming,
commented: "We are extremely pleased with the outcome of this
analysis. The data confirm the results obtained in earlier studies
and show that Rhucin® is a very fast acting product that we
expect to have great therapeutic benefits for HAE patients. Most
patients experience a relief of their, often, very painful symptoms
often within minutes after the treatment begins. The product also
has an excellent safety profile based on the results of various
studies in which, in total, well over 100 infusions were given to
subjects. Importantly, we have also never observed relapses of the
attack. We are confident that the clinical data obtained so far,
combined with preclinical and other data as well as our recently
obtained-GMP status will form a solid basis for eventual
registration of Rhucin® in Europe and elsewhere in order to
make the product available for patients who suffer from this severe
disease."

A meeting for analysts and press will be held at the offices of
Financial Dynamics in London on August 30th at 10:30 am (UK-time)
to discuss the results summarized in this press release. Copies of
the presentation and the presented data will be available on the
company's website at the start of that meeting

About Rhucin® and HAE Rhucin® (recombinant human C1
esterase inhibitor) is a human protein developed through Pharming's
proprietary technology in milk of transgenic rabbits. Rhucin®
is currently under development for treatment of patients with acute
attacks of hereditary angioedema ("HAE"). HAE is a human genetic
disorder caused by a shortage of C1 inhibitor activity and results
in an overreaction of the immune system. The disease is
characterized by acute attacks of painful and in some cases fatal
swelling of several soft tissues (edema), which may last up to five
days when untreated. In the Western world, approximately 1 in
30,000 individuals suffers from hereditary angioedema, having an
average of seven acute attacks per year.

Pharming has filed a Marketing Authorization Application for
Rhucin® in Europe. Based on the timelines associated with the
review of this product, Pharming expects an opinion of the
scientific committee of the EMEA later this year. In the USA,
Pharming aims to finalize its placebo-controlled randomized
clinical trial in the second half of 2007.

About Pharming Group N.V. Pharming Group NV is developing
innovative products for the treatment of genetic disorders,
specialty products for surgical indications, intermediates for
various applications and food products. Pharming has two products
in late stage development - recombinant human C1 inhibitor for
hereditary angioedema (MAA submitted to EMEA) and human lactoferrin
for use in functional foods (GRAS notification filed with FDA). The
advanced technologies of the Company include innovative platforms
for the production of protein therapeutics, technology and
processes for the purification and formulation of these products,
as well as technologies in the field of tissue repair (via its
collaboration with Novathera) and DNA-repair (via its acquisition
of DNage BV). Additional information is available on the Pharming
website, http://www.pharming.com and on
http://www.dnage.nl

This press release contains forward looking statements that
involve known and unknown risks, uncertainties and other factors,
which may cause the actual results, performance or achievements of
the Company to be materially different from the results,
performance or achievements expressed or implied by these forward
looking statements. The press release also appears in Dutch. In the
event of any inconsistency, the English version will prevail over
the Dutch version.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.